Skip to main content

Becton Dickinson Value Stock - Dividend - Research Selection

Becton dickinson

ISIN: US0758871091 , WKN: 857675

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


BD Named as One of America's Best Large Employers

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America's Best Large Employers List 2023 by Forbes, furthering its progress against the company's environmental, social and governance (ESG) strategy.

Why Embecta Stock Popped by Nearly 13% Today

On Tuesday, shares of diabetes management company Embecta (NASDAQ: EMBC.V) managed a more than 12% rise in price. Before market open, Embecta published the figures for its first quarter of fiscal 2023. The quarter saw Embecta report a profit under generally accepted accounting principles (GAAP) of $55.4 million, or $0.96 per share; the prognosticators following the stock were modeling only $0.71.

The Dividend Aristocrats Ranked By Quality Scores


BD's (BDX) Latest Combination Test Receives the FDA's EUA

BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons.

BDX vs. WST: Which Stock Is the Better Value Option?

BDX vs. WST: Which Stock Is the Better Value Option?

Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q4 2022 Update

William von Mueffling's 13F portfolio value increased this quarter from $11.04B to $11.81B. Read more to see Cantillon Capital's holdings for Q3 2022.

Becton, Dickinson and Company (NYSE:BDX) Q1 2023 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX) Q1 2023 Earnings Call Transcript February 2, 2023 Operator: Hello, and welcome to BD’s First Fiscal Quarter of 2023 Earnings Call. At the request of BD, today’s call is being recorded, and a replay of the call will be made available on BD’s Investor Relations website on The call […]

Becton, Dickinson: Management Raising Guidance Was A Pleasant Surprise

Becton, Dickinson and Company is a leading player in the medical technology and life sciences industries. Click here for our review of BDX stock and its prospects.

BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.